Le Lézard
Classified in: Ebola virus, Health
Subjects: NPT, FVT

NIAID Director Dr. Anthony Fauci to discuss progress made in the development of a universal flu vaccine at National Press Club Headliners Luncheon July 18


WASHINGTON, June 14, 2018 /PRNewswire-USNewswire/ -- This past year's flu season killed more children than any other non-pandemic year on record, according to data released by the Centers for Disease Control and Prevention (CDC) earlier this year. As the world marks the 100-year anniversary of the Spanish flu pandemic, which killed an estimated 50 million people worldwide in 1918, the push for the development of a universal flu vaccine capable of addressing future pandemics is gaining ground ? most notably with the appropriations of an additional $40 million to the National Institute of Allergy and Infectious Diseases (NIAID) budget for a total of $100 million to develop such a vaccine, and the Bill & Melinda Gates Foundation's announcement this past spring to award $12 million to the cause.    

NATIONAL PRESS CLUB LOGO. (PRNewsFoto/NATIONAL PRESS CLUB) (PRNewsfoto/National Press Club)

Leading the research on the development of a universal flu vaccine is Dr. Anthony Fauci, Director of the NIAID. With the start of the 2018-2019 flu season just a few months away, Dr. Fauci will speak about the progress made thus far, and the challenges that lay ahead as each strain grows deadlier and public trust in vaccinations wane at a National Press Club Headliners Luncheon on Wednesday, July 18.

Dr. Fauci began his career at the National Institutes of Health (NIH) back in 1968 in the Laboratory of Clinical Investigation in NIAID, and was later appointed Chief of the Laboratory of Immunoregulation in 1980, a position he still holds to this day. Dr. Fauci was appointed Director of NIAID in 1984 and has advised five Presidents on HIV/AIDS and many other domestic and global health issues. Fauci was awarded the Presidential Medal of Freedom by President George W. Bush for his role as an architect of the President's Emergency Plan for AIDS Relief (PEPFAR), which has been responsible for saving millions of lives in sub-Saharan Africa. NIAID and Dr. Fauci have been front and center on many headline-making incidents including the anthrax attacks in 2001 and the most recent Ebola outbreak that included treating several persons who treated Ebola victims in Africa.

Lunch will be served in the club's Holeman Lounge at 12:30 p.m., with remarks beginning at 1 p.m., followed by a question-and-answer session ending at 2 p.m. Tickets cost $25 for National Press Club members (members may purchase two tickets at this rate) and $39 for all other non-member tickets. Please click here to purchase tickets to the luncheon.

For all ticketing-related questions, please email [email protected]. Tickets must be paid for at the time of purchase. To submit a question for the speaker in advance, put FAUCI in the subject line and email to [email protected]. The deadline for submitting questions in advance is 10 a.m. on the day of the luncheon.

The National Press Club is located on the 13th Floor of the National Press Building at 529 14th St., NW, Washington, D.C.

PRESS CONTACT:
Lindsay Underwood,
[email protected]
(202) 662-7561

SOURCE National Press Club


These press releases may also interest you

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:02
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....



News published on and distributed by: